NAV as on August 31, 2018:
|Performance of Reliance Pharma Fund as on 31/08/2018|
|Particulars||1 Year CAGR %||3 Year CAGR %||5 Year CAGR %||Since Inception|
|Reliance Pharma Fund ||31.19||2.41||17.79||21.57|
|B: S&P BSE Healthcare (TRI)||22.09||-3.34||12.82||15.45|
|AB: S&P BSE Sensex (TRI)||23.20||15.22||17.32||16.93|
|Reliance Pharma Fund ||13,119||10,742||22,697||161,571|
|B: S&P BSE Healthcare (TRI)||12,209||9,029||18,288||77,493|
|AB: S&P BSE Sensex (TRI)||12,320||15,300||22,243||92,927|
Inception Date: Jun 5, 2004|
|B - Benchmark | AB - Additional Benchmark | TRI - Total Return Index |
|Fund Manager: Sailesh Raj Bhan (Since Jun 2004)|
|As TRI data is not available since inception of the scheme, benchmark performance is calculated using composite CAGR of S&P BSE Healthcare PRI values from 04/06/2004 to 31/12/2007 and TRI values since 31/12/2007. |
|As TRI data is not available since inception of the scheme, benchmark performance is calculated using composite CAGR of S&P BSE Sensex PRI values from 04/06/2004 to 31/05/2007 and TRI values since 31/05/2007. |
PERFORMANCE OF OTHER OPEN ENDED SCHEMES MANAGED BY FUND MANAGER: Sailesh Raj Bhan
|Scheme Name/s||CAGR %|
|1 Year Return ||3 Years Return||5 Years Return|
|Scheme ||Benchmark ||Scheme ||Benchmark ||Scheme ||Benchmark |
|Reliance Consumption Fund||12.18||20.60||10.40||17.56||16.03||19.84|
|Reliance Multi Cap Fund||14.13||16.53||9.88||16.02||21.17||20.42|
|Reliance Large Cap Fund||16.55||18.02||14.16||15.51||22.85||18.75|
a.Mr. Shailesh Raj Bhan manages 4 open-ended schemes of Reliance Mutual Fund.
b. In case the number of schemes managed by a fund manager is more than six, in the performance data of other schemes, the top 3 and bottom 3 schemes managed by fund manager has been provided herein.
c. Period for which scheme’s performance has been provided is computed basis last day of the month-end preceding the date of advertisement.
d. Different plans shall have a different expense structure. The performance details provided herein are of Growth Plan (Regular Plan).
TRI - Total Returns Index reflects the returns on the index arising from (a) constituent stock price movements and (b) dividend receipts from constituent index stocks, thereby showing a true picture of returns.
The performance of the equity scheme is benchmarked to the Total Return variant of the Index.
Mr. Sailesh Raj Bhan has been managing Reliance Pharma Fund since Jun 2004, Reliance Consumption Fund since Sep 2004, Reliance Multi Cap Fund since Mar 2005, Reliance Large Cap Fund since Aug 2007
Past performance may or may not be sustained in future and the same may not necessarily provide the basis for comparison with other Investment. Dividends (if any) are assumed to be reinvested at the prevailing NAV. In case of LIQUIDBEES, returns are based on gross dividend per unit declared by the Fund. Bonus (if any) declared has been adjusted. Performance of dividend option would be Net of Dividend distribution tax, if any. Face value of scheme is
`10/- per unit. Face Value of Reliance Low Duration Fund is
`1000/- per unit. Face Value of Reliance Money Market Fund, Reliance Liquid Fund, Reliance Ultra Short Duration Fund is
`1000/- per unit w.e.f 5th Aug 2012. Face value of Reliance ETF Junior BeES is
`1.25/- per unit. Face value of Reliance ETF Liquid BeES is
`1000/- per unit. Face value of Reliance ETF Gold BeES is
`100/- per unit. In case, the start/end date of the concerned period is non-business day (NBD), the NAV of the previous date is considered for computation of returns. Schemes which have not completed one year, performance details for the same are not provided. Performance details of closed ended schemes are not provided since these are not comparable with other schemes.Different plans shall have a different expense structure. The performance details provided herein are of Growth Plan (Regular Plan).